Search

Your search keyword '"Opyrchal, Mateusz"' showing total 315 results
Start Over Author "Opyrchal, Mateusz"
315 results on '"Opyrchal, Mateusz"'

1. Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity

Author

Khaliq, Ateeq M., Rajamohan, Meenakshi, Saeed, Omer, Mansouri, Kimia, Adil, Asif, Zhang, Chi, Turk, Anita, Carstens, Julienne L., House, Michael, Hayat, Sikander, Nagaraju, Ganji P., Pappas, Sam G., Wang, Y. Alan., Zyromski, Nicholas J., Opyrchal, Mateusz, Lee, Kelvin P., O’Hagan, Heather, El Rayes, Bassel, and Masood, Ashiq

Published
2024
Full Text
View/download PDF

2. Downregulation of IRF8 in alveolar macrophages by G-CSF promotes metastatic tumor progression

Author

Tzetzo, Stephanie L., Kramer, Elliot D., Mohammadpour, Hemn, Kim, Minhyung, Rosario, Spencer R., Yu, Han, Dolan, Melissa R., Oturkar, Chetan C., Morreale, Brian G., Bogner, Paul N., Stablewski, Aimee B., Benavides, Fernando J., Brackett, Craig M., Ebos, John M.L., Das, Gokul M., Opyrchal, Mateusz, Nemeth, Michael J., Evans, Sharon S., and Abrams, Scott I.

Published
2024
Full Text
View/download PDF

3. A phase II study of palbociclib plus letrozole plus trastuzumab as neoadjuvant treatment for clinical stages II and III ER+ HER2+ breast cancer (PALTAN)

Author

Ademuyiwa, Foluso O., Northfelt, Donald W., O’Connor, Tracey, Levine, Ellis, Luo, Jingqin, Tao, Yu, Hoog, Jeremy, Laury, Marie L., Summa, Tracy, Hammerschmidt, Trish, Guo, Zhanfang, Frith, Ashley, Weilbaecher, Katherine, Opyrchal, Mateusz, Aft, Rebecca, Clifton, Katherine, Suresh, Rama, Bagegni, Nusayba, Hagemann, Ian S., Iglesia, Michael D., and Ma, Cynthia X.

Published
2023
Full Text
View/download PDF

6. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer

Author

Yara Abdou, Medhavi Gupta, Mariko Asaoka, Kristopher Attwood, Opyrchal Mateusz, Shipra Gandhi, and Kazuaki Takabe

Subjects
Medicine, Science
Abstract

Abstract Breast cancer is more common on the left side than the right side. We aim to evaluate differences in clinicopathological and genomic characteristics based on laterality. We analyzed survival outcomes and clinical characteristics of 881,320 patients recorded by the Surveillance, Epidemiology, and End Results (SEER) program. The Cancer Genome Atlas (TCGA) was used to explore genomic and clinical features from 1,062 patients. Gene expression data was used to quantitate cytolytic activity and hallmark gene-sets were used for gene set enrichment analysis. An institutional retrospective review was conducted on 155 patients treated with neoadjuvant chemotherapy (NACT). Patient characteristics were summarized by pathological complete response (pCR). Left sided tumors were found to be more prevalent than right sided tumors. No major clinicopathological differences were noted by laterality. Left sided breast cancer demonstrated poorer outcomes versus right sided tumors (HR 1.05, 95% CI 1.01–1.08; p = 0.011). Cell proliferation gene sets, including E2F Targets, G2M Checkpoint, Mitotic spindle, and MYC Targets, were enriched on the left side compared to the right. Left sided tumors had lower pCR rates versus right sided tumors (15.4% versus 29.9%, p = 0.036). Our findings suggest that left sided breast cancer is associated with aggressive biology and worse outcomes compared to right sided breast cancer.

Published
2022
Full Text
View/download PDF

7. Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

Author

Davis, Andrew A., Gerratana, Lorenzo, Clifton, Katherine, Medford, Arielle J., Velimirovic, Marko, Hensing, Whitney L., Bucheit, Leslie, Shah, Ami N., D'Amico, Paolo, Reduzzi, Carolina, Zhang, Qiang, Dai, Charles S., Denault, Elyssa N., Bagegni, Nusayba A., Opyrchal, Mateusz, Ademuyiwa, Foluso O., Bose, Ron, Gradishar, William J., Behdad, Amir, Ma, Cynthia X., Bardia, Aditya, and Cristofanilli, Massimo

Published
2022
Full Text
View/download PDF

11. Immunogenomic profiling and pathological response results from a clinical trial of docetaxel and carboplatin in triple-negative breast cancer

Author

Ademuyiwa, Foluso O., Chen, Ina, Luo, Jingqin, Rimawi, Mothaffar F., Hagemann, Ian S., Fisk, Bryan, Jeffers, Gejae, Skidmore, Zachary L., Basu, Anamika, Richters, Megan, Ma, Cynthia X., Weilbaecher, Katherine, Davis, Jennifer, Suresh, Rama, Peterson, Lindsay L., Bose, Ron, Bagegni, Nusayba, Rigden, Caron E., Frith, Ashley, Rearden, Timothy P., Hernandez-Aya, Leonel F., Roshal, Anna, Clifton, Katherine, Opyrchal, Mateusz, Akintola-Ogunremi, Olaronke, Lee, Byung Ha, Ferrando-Martinez, Sara, Church, Sarah E., Anurag, Meenakshi, Ellis, Matthew J., Gao, Feng, Gillanders, William, Griffith, Obi L., and Griffith, Malachi

Published
2021
Full Text
View/download PDF

12. A Phase I Study of sequences of the CDK4/6 Inhibitor, Ribociclib Combined with Gemcitabine in Patients with Advanced Solid Tumors

Author

Seetharam, Mahesh, primary, Norman, Aurora, additional, Allred, Jacob, additional, Kong, Jianping, additional, Opyrchal, Mateusz, additional, Ma, Wen Wee, additional, Lou, Yanyan, additional, Dy, Grace K, additional, Mahipal, Amit, additional, Weroha, John, additional, Wahner-Hendrickson, Andrea, additional, Reid, Joel M., additional, and Adjei, Alex A., additional

Published
2024
Full Text
View/download PDF

14. A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors

Author

Janku, Filip, primary, Choong, Grace M., additional, Opyrchal, Mateusz, additional, Dowlati, Afshin, additional, Hierro, Cinta, additional, Rodon, Jordi, additional, Wicki, Andreas, additional, Forster, Martin D., additional, Blagden, Sarah P., additional, Yin, Jun, additional, Reid, Joel M., additional, Muller, Helene, additional, Cmiljanovic, Natasa, additional, Cmiljanovic, Vladimir, additional, and Adjei, Alex A., additional

Published
2024
Full Text
View/download PDF

15. A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors

Author

Juric, Dejan, primary, Barve, Minal, additional, Vaishampayan, Ulka, additional, Roda, Desamparados, additional, Calvo, Aitana, additional, Jañez, Noelia Martinez, additional, Trigo, Jose, additional, Greystoke, Alastair, additional, Harvey, R. Donald, additional, Olszanski, Anthony J., additional, Opyrchal, Mateusz, additional, Spira, Alexander, additional, Thistlethwaite, Fiona, additional, Jiménez, Begoña, additional, Sappal, Jessica Huck, additional, Kannan, Karuppiah, additional, Riley, Jason, additional, Li, Cheryl, additional, Li, Cong, additional, Gregory, Richard C., additional, Miao, Harry, additional, and Wang, Shining, additional

Published
2024
Full Text
View/download PDF

18. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression

Author

Colligan, Sean H., Amitrano, Andrea M., Zollo, Robert A., Peresie, Jennifer, Kramer, Elliot D., Morreale, Brian, Barbi, Joseph, Singh, Prashant K., Yu, Han, Wang, Jianmin, Opyrchal, Mateusz, Sykes, David B., Nemeth, Michael J., and Abrams, Scott I.

Subjects
Suppressor cells -- Health aspects -- Physiological aspects, Immunological research, Bone marrow cells -- Health aspects -- Physiological aspects, Breast tumors -- Care and treatment -- Development and progression, Biosynthesis -- Research, Cell development (Biology) -- Research, Immunotherapy -- Methods, Health care industry
Abstract

While immune checkpoint inhibitors (ICIs) have transformed the therapeutic landscape in oncology, they are effective in select subsets of patients. Efficacy may be limited by tumor-driven immune suppression, of which 1 key mechanism is the development of myeloid-derived suppressor cells (MDSCs). A fundamental gap in MDSC therapeutics is the lack of approaches that target MDSC biogenesis. We hypothesized that targeting MDSC biogenesis would mitigate MDSC burden and bolster tumor responses to ICIs. We tested a class of agents, dihydroorotate dehydrogenase (DHODH) inhibitors, that have been previously shown to restore the terminal differentiation of leukemic myeloid progenitors. DHODH inhibitors have demonstrated preclinical safety and are under clinical study for hematologic malignancies. Using mouse models of mammary cancer that elicit robust MDSC responses, we demonstrated that the DHODH inhibitor brequinar (a) suppressed MDSC production from early-stage myeloid progenitors, which was accompanied by enhanced myeloid maturation; (b) augmented the antitumor and antimetastatic activities of programmed cell death 1-based (PD-1-based) ICI therapy in ICI-resistant mammary cancer models; and (c) acted in concert with PD-1 blockade through modulation of MDSC and [CD8.sup.+] T cell responses. Moreover, brequinar facilitated myeloid maturation and inhibited immune-suppressive features in human bone marrow culture systems. These findings advance the concept of MDSC differentiation therapy in immuno-oncology., Introduction The ability to harness the immune system through immunotherapy, namely immune checkpoint inhibitors (ICIs), has improved survival for patients with advanced cancers of diverse types, including renal cancer, non-small [...]

Published
2022
Full Text
View/download PDF

20. Harnessing tumorous flaws for immune supremacy: is miRNA-155 the weak link in breast cancer progression?

Author

Sharma, Samantha, Opyrchal, Mateusz, and Lu, Xiongbin

Subjects
Cytokines -- Analysis, Immunotherapy -- Patient outcomes, MicroRNA -- Analysis, Breast cancer -- Diagnosis -- Care and treatment, Health care industry
Abstract

With the advent of immune checkpoint blockade (ICB) therapy, treatment strategies for late-stage cancers have seen a radical advancement. In this issue of theJCI, Wang et al. characterize the functional role of miR-155 in breast cancer and its potential in harnessing the efficacy of immunotherapy. The study reports that high expression levels of miR-155 in breast cancer cells downregulated suppressor of cytokine signaling 1 (SOCS1), increased the phosphorylated STAT1 (pSTAT1)/pSTAT3 ratio, and thereby stimulated chemoattractants for tumor infiltration of effector T cells. Moreover, miR-155 overexpression set the stage for ICB therapy via increased programmed death ligand 1 (PD-L1) expression on cancer cells and enhanced immunological memory response via the release of miR-155-containing extracellular vesicles. Collectively, these data suggest that miR-155 is a strong candidate as a prognostic biomarker for ICB therapy., miRNAs at the crossroads between inflammation and cancer For decades, researchers have speculated that inflammation and cancer are like a fighting pair in a relationship (1). Further igniting the mystery, [...]

Published
2022
Full Text
View/download PDF

21. Adaptive phase I–II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies.

Author

Zang, Yong, Guo, Beibei, Qiu, Yingjie, Liu, Hao, Opyrchal, Mateusz, and Lu, Xiongbin

Subjects
DRUG toxicity, PHYSIOLOGICAL adaptation, PATIENT safety, CLINICAL trials, IMMUNOTHERAPY, DOSE-effect relationship in pharmacology, DOSAGE forms of drugs, DRUG efficacy, QUALITY of life, GENETIC techniques, SURVIVAL analysis (Biometry)
Abstract

Targeted agents and immunotherapies have revolutionized cancer treatment, offering promising options for various cancer types. Unlike traditional therapies the principle of "more is better" is not always applicable to these new therapies due to their unique biomedical mechanisms. As a result, various phase I–II clinical trial designs have been proposed to identify the optimal biological dose that maximizes the therapeutic effect of targeted therapies and immunotherapies by jointly monitoring both efficacy and toxicity outcomes. This review article examines several innovative phase I–II clinical trial designs that utilize accumulated efficacy and toxicity outcomes to adaptively determine doses for subsequent patients and identify the optimal biological dose, maximizing the overall therapeutic effect. Specifically, we highlight three categories of phase I–II designs: efficacy-driven, utility-based, and designs incorporating multiple efficacy endpoints. For each design, we review the dose–outcome model, the definition of the optimal biological dose, the dose-finding algorithm, and the software for trial implementation. To illustrate the concepts, we also present two real phase I–II trial examples utilizing the EffTox and ISO designs. Finally, we provide a classification tree to summarize the designs discussed in this article. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Author

Gandhi, Shipra, primary, Opyrchal, Mateusz, additional, Grimm, Melissa J, additional, Slomba, Ronald T, additional, Kokolus, Kathleen M, additional, Witkiewicz, Agnieszka, additional, Attwood, Kristopher, additional, Groman, Adrienne, additional, Williams, Lauren, additional, Tarquini, Mary Lynne, additional, Wallace, Paul K, additional, Soh, Kah Teong, additional, Minderman, Hans, additional, Maguire, Orla, additional, O’Connor, Tracey L, additional, Early, Amy P, additional, Levine, Ellis G, additional, and Kalinski, Pawel, additional

Published
2023
Full Text
View/download PDF

27. Data from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Tables 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

29. Supplemental Figure 3 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

30. Supplemental Figure 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data 1 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

32. Supplemental Figure 2 from Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, primary, Clifton, Katherine, primary, Medford, Arielle J., primary, Velimirovic, Marko, primary, Shah, Ami N., primary, D'Amico, Paolo, primary, Reduzzi, Carolina, primary, Zhang, Qiang, primary, Dai, Charles S., primary, Denault, Elyssa N., primary, Bagegni, Nusayba A., primary, Opyrchal, Mateusz, primary, Ademuyiwa, Foluso O., primary, Bose, Ron, primary, Behdad, Amir, primary, Ma, Cynthia X., primary, Bardia, Aditya, primary, Cristofanilli, Massimo, primary, and Davis, Andrew A., primary

Published
2023
Full Text
View/download PDF

33. Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer

Author

Hensing, Whitney L., primary, Gerratana, Lorenzo, additional, Clifton, Katherine, additional, Medford, Arielle J., additional, Velimirovic, Marko, additional, Shah, Ami N., additional, D'Amico, Paolo, additional, Reduzzi, Carolina, additional, Zhang, Qiang, additional, Dai, Charles S., additional, Denault, Elyssa N., additional, Bagegni, Nusayba A., additional, Opyrchal, Mateusz, additional, Ademuyiwa, Foluso O., additional, Bose, Ron, additional, Behdad, Amir, additional, Ma, Cynthia X., additional, Bardia, Aditya, additional, Cristofanilli, Massimo, additional, and Davis, Andrew A., additional

Published
2023
Full Text
View/download PDF

34. A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Author

Zhou, Zhuolong, primary, Van der Jeught, Kevin, additional, Li, Yujing, additional, Sharma, Samantha, additional, Yu, Tao, additional, Moulana, Ishara, additional, Liu, Sheng, additional, Wan, Jun, additional, Territo, Paul R., additional, Opyrchal, Mateusz, additional, Zhang, Xinna, additional, Wan, Guohui, additional, and Lu, Xiongbin, additional

Published
2023
Full Text
View/download PDF

37. Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing

Author

Dy, Grace K., Nesline, Mary K., Papanicolau-Sengos, Antonios, DePietro, Paul, LeVea, Charles M., Early, Amy, Chen, Hongbin, Grand’Maison, Anne, Boland, Patrick, Ernstoff, Marc S., Edge, Stephen, Akers, Stacey, Opyrchal, Mateusz, Chatta, Gurkamal, Odunsi, Kunle, Pabla, Sarabjot, Conroy, Jeffrey M., Glenn, Sean T., DeFedericis, Hanchun T., Burgher, Blake, Andreas, Jonathan, Giamo, Vincent, Qin, Maochun, Wang, Yirong, Kanehira, Kazunori, Lenzo, Felicia L., Frederick, Peter, Lele, Shashikant, Galluzzi, Lorenzo, Kuvshinoff, Boris, and Morrison, Carl

Published
2019
Full Text
View/download PDF

38. Abstract CT254: Trial in progress: a first-in-human, phase 1, multicenter dose escalation and dose expansion study of WTX-330 in adult patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma

Author

Rodriguez-Rivera, Ildefonso Ismael, primary, Moser, Justin C., additional, Opyrchal, Mateusz, additional, Parikh, Aparna R., additional, Park, Saero, additional, Bruno, Marissa, additional, Windt, Paul, additional, Subramanian, Kulandayan K., additional, Chopra, Sameer S., additional, and Isaacs, Randi, additional

Published
2023
Full Text
View/download PDF

39. Abstract CT133: Trial in progress: a multicenter phase 1/1b dose escalation study of WTX-124 as a monotherapy and in combination with pembrolizumab in patients with selected advanced or metastatic solid tumors

Author

Rodriguez-Rivera, Ildefonso Ismael, primary, Moser, Justin C., additional, Opyrchal, Mateusz, additional, Curti, Brendan, additional, Bilen, Mehmet A., additional, Park, Saero, additional, Bruno, Marissa, additional, Windt, Paul, additional, Subramanian, Kulandayan K., additional, Chopra, Sameer S., additional, and Isaacs, Randi, additional

Published
2023
Full Text
View/download PDF

40. Supplementary Figure F1 from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates

Author

Malhotra, Usha, primary, Mukherjee, Sarbajit, primary, Fountzilas, Christos, primary, Boland, Patrick, primary, Miller, Austin, primary, Patnaik, Santosh, primary, Attwood, Kristopher, primary, Yendamuri, Sai, primary, Adjei, Araba, primary, Kannisto, Eric, primary, Opyrchal, Mateusz, primary, Bushunow, Peter, primary, Loud, Peter, primary, Iyer, Renuka, primary, and Khushalani, Nikhil, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Tables from Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates

Author

Malhotra, Usha, primary, Mukherjee, Sarbajit, primary, Fountzilas, Christos, primary, Boland, Patrick, primary, Miller, Austin, primary, Patnaik, Santosh, primary, Attwood, Kristopher, primary, Yendamuri, Sai, primary, Adjei, Araba, primary, Kannisto, Eric, primary, Opyrchal, Mateusz, primary, Bushunow, Peter, primary, Loud, Peter, primary, Iyer, Renuka, primary, and Khushalani, Nikhil, primary

Published
2023
Full Text
View/download PDF

42. Abstract P3-06-07: Phase Ib/II study to evaluate safety and tolerability of cabiralizumab in combination with nivolumab and neoadjuvant chemotherapy in patients with localized triple-negative breast cancer

Author

Davis, Andrew A., primary, Hernandez-Aya, Leonel, additional, Luo, Jingqin, additional, Opyrchal, Mateusz, additional, Ademuyiwa, Foluso O., additional, Bagegni, Nusayba A., additional, Clifton, Katherine K., additional, Anderson, Jill, additional, Hammerschmidt, Trish, additional, Nehring, Leslie, additional, DeNardo, David, additional, Watson, Mark, additional, Aft, Rebecca, additional, Ma, Cynthia, additional, and Weilbaecher, Katherine, additional

Published
2023
Full Text
View/download PDF

48. Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Author

Evans, Rachel, primary, Lee, Kelvin, additional, Wallace, Paul K., additional, Reid, Mary, additional, Muhitch, Jason, additional, Dozier, Askia, additional, Mesa, Circe, additional, Luaces, Patricia L., additional, Santos-Morales, Orestes, additional, Groman, Adrienne, additional, Cedeno, Carlos, additional, Cinquino, Aileen, additional, Fisher, Daniel T., additional, Puzanov, Igor, additional, Opyrchal, Mateusz, additional, Fountzilas, Christos, additional, Dai, Tong, additional, Ernstoff, Marc, additional, Attwood, Kristopher, additional, Hutson, Alan, additional, Johnson, Candace, additional, Mazorra, Zaima, additional, Saavedra, Danay, additional, Leon, Kalet, additional, Lage, Agustin, additional, Crombet, Tania, additional, and Dy, Grace K., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results